spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  bispecific antibody 

 HSMN NewsFeed - 6 Aug 2026
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2026
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Jun 2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 May 2026
Partner Therapeutics Announces FDA Approval of BIZENGRI(R) (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2026
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2026
Harbour BioMed Appoints Dr. Adam Zong as President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2026
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2025
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Aug 2025
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4R?) for Atopic Dermatitis Achieve Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2024
Compugen Appoints David Silberman as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Feb 2023
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2022
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Jul 2021
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2020
Novo Ventures co-leads US $83m series C financing in Lava Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 16 Jan 2018
Geoffrey B. Davis Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2015
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2014
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jul 2012
NovImmune Strengthens Board and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2012
Sutro Closes $16.5 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 9 Dec 2011
Immunomedics Creates Targeted Therapeutics for Solid Cancers
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
bispecific antibody
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!